Gowtham Jayakumaran
Overview
Explore the profile of Gowtham Jayakumaran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
3951
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ziegler J, Hechtman J, Rana S, Ptashkin R, Jayakumaran G, Middha S, et al.
Nat Commun
. 2025 Jan;
16(1):136.
PMID: 39746944
Microsatellite instability (MSI) is a critical phenotype of cancer genomes and an FDA-recognized biomarker that can guide treatment with immune checkpoint inhibitors. Previous work has demonstrated that next-generation sequencing data...
2.
Yang S, Jayakumaran G, Benhamida J, Febres-Aldana C, Fanaroff R, Chang J, et al.
Clin Cancer Res
. 2024 Apr;
30(13):2780-2789.
PMID: 38630790
Purpose: Diffuse pleural mesotheliomas (DPM) with genomic near-haploidization (GNH) represent a novel subtype first recognized by The Cancer Genome Atlas project; however, its clinicopathologic and molecular features remain poorly defined....
3.
Ptashkin R, Ewalt M, Jayakumaran G, Kiecka I, Bowman A, Yao J, et al.
Nat Commun
. 2023 Oct;
14(1):6895.
PMID: 37898613
Genomic profiling of hematologic malignancies has augmented our understanding of variants that contribute to disease pathogenesis and supported development of prognostic models that inform disease management in the clinic. Tumor...
4.
Abramson D, Mandelker D, Brannon A, Dunkel I, Benayed R, Berger M, et al.
PLoS One
. 2023 Feb;
18(2):e0271505.
PMID: 36735656
Cell free DNA (cfDNA) and circulating tumor cell free DNA (ctDNA) from blood (plasma) are increasingly being used in oncology for diagnosis, monitoring response, identifying cancer causing mutations and detecting...
5.
Jee J, Lebow E, Yeh R, Das J, Namakydoust A, Paik P, et al.
Nat Med
. 2022 Nov;
28(11):2353-2363.
PMID: 36357680
Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively followed an...
6.
Abramson D, Mandelker D, Francis J, Dunkel I, Brannon A, Benayed R, et al.
Ophthalmol Sci
. 2022 Oct;
1(1):100015.
PMID: 36246006
Purpose: Analysis of circulating tumor DNA (ctDNA) in the plasma of patients with retinoblastoma and simulating lesions. Design: Retrospective cross-sectional study of the association of plasma ctDNA from retinoblastoma and...
7.
Ceyhan-Birsoy O, Jayakumaran G, Kemel Y, Misyura M, Aypar U, Jairam S, et al.
Genome Med
. 2022 Aug;
14(1):92.
PMID: 35971132
Background: Genetic testing (GT) for hereditary cancer predisposition is traditionally performed on selected genes based on established guidelines for each cancer type. Recently, expanded GT (eGT) using large hereditary cancer...
8.
Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan S, Richards A, et al.
Nat Genet
. 2021 Nov;
53(11):1577-1585.
PMID: 34741162
Human cancers arise from environmental, heritable and somatic factors, but how these mechanisms interact in tumorigenesis is poorly understood. Studying 17,152 prospectively sequenced patients with cancer, we identified pathogenic germline...
9.
Offin M, Yang S, Egger J, Jayakumaran G, Spencer R, Lopardo J, et al.
J Thorac Oncol
. 2021 Oct;
17(3):455-460.
PMID: 34648949
Introduction: Malignant peritoneal mesothelioma (MPeM) is clinically distinct and less studied than malignant pleural mesothelioma. We report the genomic and immunophenotypic features of a prospectively collected MPeM cohort. Methods: Next-generation...
10.
Fiala E, Jayakumaran G, Mauguen A, Kennedy J, Bouvier N, Kemel Y, et al.
Nat Cancer
. 2021 Jul;
2:357-365.
PMID: 34308366
The spectrum of germline predisposition in pediatric cancer continues to be realized. Here we report 751 solid tumor patients who underwent prospective matched tumor-normal DNA sequencing and downstream clinical use...